Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q2 2026 · 10-Q
Revenue$350.00K$350.00K−48.3% vs Q2 2025 Net Income-$83.71M-$83.71MN/M vs Q2 2025 EPS Diluted-$0.41-$0.41N/M vs Q2 2025 Operating Income-$90,824,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-25949.7%−14598.6 pt vs Q2 2025
Net margin-23916.3%−13521.2 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end